| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:22146484 | IVR | 1 mg/kg | 1 mg/kg | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Changes in morphology of cervix | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | - | No significant effects observed | - | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:23399300 | IVTH | 0.000000003 - 0.0000003 M | 0.00000001 - 0.0000003 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000003 - 0.0000003 M | 0.00000003 - 0.0000003 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000003 - 0.0000003 M | 0.0000003 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:23764977 | IVTH | 0.000000001 - 0.0001 M | 0.000029 - 0.000065 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| PMID:23978332 | IVTH | 0.00000001 - 0.0001 M | 0.00001 - 0.0001 M | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.0001 M | 0.00001 - 0.0001 M | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations | |
| PMID:24940614 | IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1.25 mg/kg/day | 1.25 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1.25 mg/kg/day | 1.25 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1.25 mg/kg/day | 1.25 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1.25 mg/kg/day | 1.25 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.31 mg/kg/day | 0.31 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:25827101 | IVR | 0.003 - 3 mg/kg | 0.3 - 3 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 0.003 - 3 mg/kg | 0.3 - 3 mg/kg | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.003 - 3 mg/kg | 0.3 - 3 mg/kg | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| PMID:26234195 | IVTH | 0.000000001 - 0.0000001 M | 0.000000001 - 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:27139122 | IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:29502166 | IVTH | 0.00005 M | - | No significant effects observed | - |
| IVTH | 0.0001 M | 0.0001 M | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.0001 M | 0.0001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| IVTH | 0.0001 M | 0.0001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:29601859 | IVTH | 100 M | 100 M | Increased estrone levels | Reproductive endocrine-mediated perturbations |
| PMID:29721586 | IVR | 20 mg/kg/day | 20 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVR | 1.25 mg/kg/day | 1.25 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30414542 | IVTH | 0.2 mg/L | 0.2 mg/L | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.2 mg/L | 0.2 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.002 mg/L | 0.002 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.002 mg/L | 0.002 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 2 mg/L | 2 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 2 mg/L | 2 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00002 mg/L | 0.00002 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.00002 mg/L | 0.00002 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.02 mg/L | 0.02 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.02 mg/L | 0.02 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0002 mg/L | 0.0002 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.0002 mg/L | 0.0002 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:31707300 | IVR | 15 mg/kg/day | 15 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| PMID:31923581 | IVTH | 0.0002 mg/L | - | No significant effects observed | - |
| IVTH | 0.002 mg/L | 0.002 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.002 mg/L | 0.002 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.02 mg/L | 0.02 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.02 mg/L | 0.02 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.